ReviewFrontiers in immunology2021
Precision Vaccine Development: Cues From Natural Immunity.
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 33 citations in OpenAlex.
- High-dimensional profiling following third MMR vaccination or mumps virus infection reveals individuals with suboptimal immunity.Communications medicine · 2026Article
- Live Attenuated Influenza Virus as a Vector for Multivalent T-Cell Vaccines: Targeting RSV, hMPV, and PIV3.Vaccines · 2026Article
- The nanoemulsion adjuvant provides antigen dose-sparing effects and enhances maternal passive immune protection for the cell-cultured quadrivalent influenza virus subunit vaccine.Virology journal · 2026Article
- Discovery of a small molecule TLR3 agonist adjuvant.Nature communications · 2025Article
- Review
- Humoral and Memory B Cell Responses Following SARS-CoV-2 Infection and mRNA Vaccination.Vaccines · 2025Article
- The Application of Single-Cell Technologies for Vaccine Development Against Viral Infections.Vaccines · 2025Review
- OMIP-111: Immune-Profiling of T Helper 1 (Th1), Th2, and Th17 Signatures in Murine Splenocytes by Targeting Intracellular Cytokines.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2025Article
- Kinetically activating nanovaccine mimicking multidimensional immunomodulation of natural infection for broad protection against heterologous viruses in animal models.Nature communications · 2025Article
- Immune responses to human papillomavirus infection and vaccination.Frontiers in immunology · 2025Review
- Impact of lactobacillus probiotics on vaccine response in diabetic rats: modulation of inflammatory cytokines.American journal of clinical and experimental immunology · 2025Article
- A vaccine platform targeting lung-resident memory CD4Nature communications · 2024Article
- Article
- Modulation of the Adjuvant Potential of Imidazoquinoline-Based TLR7/8 Agonists via Alum Adsorption.ACS medicinal chemistry letters · 2024Article
- Precision Nanovaccines for Potent Vaccination.JACS Au · 2024Review
- From hit to vial: Precision discovery and development of an imidazopyrimidine TLR7/8 agonist adjuvant formulation.Science advances · 2024Article
- Immune profiling of age and adjuvant-specific activation of human blood mononuclear cells in vitro.Communications biology · 2024Article
- Article
- The immune response to Covid-19 mRNA vaccination among Lymphoma patients receiving anti-CD20 treatment.Frontiers in immunology · 2024Article
- Human in vitro modeling of adjuvant formulations demonstrates enhancement of immune responses to SARS-CoV-2 antigen.NPJ vaccines · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Traditional vaccine development against infectious diseases has been guided by the overarching aim to generate efficacious vaccines normally indicated by an antibody and/or cellular response that correlates with protection. However, this approach has been shown to be only a partially effective measure, since vaccine- and pathogen-specific immunity may not perfectly overlap. Thus, some vaccine development strategies, normally focused on targeted generation of both antigen specific antibody and T cell responses, resulting in a long-lived heterogenous and stable pool of memory lymphocytes, may benefit from better mimicking the immune response of a natural infection. However, challenges to achieving this goal remain unattended, due to gaps in our understanding of human immunity and full elucidation of infectious pathogenesis. In this review, we describe recent advances in the development of effective vaccines, focusing on how understanding the differences in the immunizing and non-immunizing immune responses to natural infections and corresponding shifts in immune ontogeny are crucial to inform the next generation of infectious disease vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.